Myasthenia Gravis: A Rare Neurologic Complication of Immune Checkpoint Inhibitor Therapy
Shames A, et al
Published in Journal of the Advanced Practitioner in Oncology
Methodology
Single-patient case report with clinical narrative and review of drugs known to exacerbate myasthenia gravis in the oncology setting.
Key Findings
This case report describes immune checkpoint inhibitor-associated myasthenia gravis and notes that magnesium-containing agents, including magnesium sulfate, can unmask or worsen myasthenic weakness through impaired neuromuscular transmission.
Conclusions
Magnesium sulfate is among agents known to unmask or exacerbate myasthenia gravis symptoms.
Limitations
Single case with no control or causal inference; the magnesium caution derives from pharmacological reasoning and prior reports, not from a trial.
Supplements Studied
Many medications, including fluroquinolone, aminoglycoside, magnesium sulfate, quinidine, and select beta blockers, are known to unmask or exacerbate symptoms of myasthenia gravis.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.